The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells Leukemia (2016) 30, 1784-1788; doi:10.1038/leu. 2016.56 Mutations/deletions of the TET2 gene frequently occur in multiple spectra of myeloid malignancies, including myelodysplastic syndrome, myeloproliferative neoplasm (MPN), acute myeloid leukemia and chronic myelomonocytic leukemia (CMML). [1] [2] [3] [4] TET2 mutations/ deletions are often heterozygous and ancestral in these myeloid malignancies. [1] [2] [3] [4] TET2 plays an important role in hematopoietic stem cell (HSC) biology, and Tet2 loss leads to an increased HSC selfrenewal and skewed differentiation favoring granulocytic/monocytic lineage. [5] [6] [7] [8] Furthermore, Tet2-deletion (Tet2 − / − ) or -haploinsufficiency (Tet2 +/ − ) leads to myeloid malignancies in mice. [5] [6] [7] TET2, therefore, acts as a tumor suppressor in hematopoiesis.
The TET family of proteins shares the conserved Cys-rich domain and double-stranded beta helix domain, which are the catalytic center of Fe 2+ -and 2-oxoglutarate-dependent dioxygenases. 9 TETs exhibit unique enzymatic function to facilitate the DNA demethylation process, oxidizing 5-methylcytosine to 5-hydroxymethylcytosin (5hmC), 5-formylcytosine and 5-carboxylcytosine in a stepwise manner. [10] [11] [12] Giving the prominent role of TET2 in the pathogenesis of myeloid malignancies, TET2 and its pathways represent potential therapeutic targets for intervention. Therefore, it is important to clarify whether the catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function. In addition, although myeloid malignancies are clonal disorders of HSC/progenitor cells (HSC/HPCs), it remains to be established at which HSC developmental stages, TET2 loss is capable of inducing myeloid malignancies. In this study, using mice with lineage specific Tet2-inactivation and transplantation assays, we reveal that Tet2 loss in HSC/HPCs, but not more differentiated cells, are capable of inducing myeloid malignancies. By examining the ability of wild-type (WT) and catalytic inactive mutant TET2 to rescue the in vitro hyper-replating potential and in vivo myeloid malignancyinitiating capacity of Tet2 − / − HSC/HPCs, we demonstrate that the TET2 catalytic activity is essential and critical for its myeloid malignancy-suppressive function in HSC/HPCs.
We first examined the presence of TET2 mutations in bone marrow (BM) CD34 + , CD33 + , CD19 + and CD3 + cell populations purified from myeloid malignancy patients with known TET2 mutations. TET2 mutations were present in each of the CD34 + , CD33 + and CD19 + , but not CD3 + , cell populations from all three patients examined (Figure 1a and Supplementary Figure S1A ), indicating the occurrence of TET2 mutations at the common myeloid-B-progenitor level. Such primitive progenitor cells have Accepted article preview online 8 March 2016; advance online publication, 22 March 2016 been described. 13 Deletion of Tet2 leads to myeloid malignancies in mice. [5] [6] [7] We next investigated at which HSC differentiation stages TET2 loss is capable of inducing myeloid malignancies. We first generated Tet2 f/f ;LysMCre mice, 14 in which Tet2 is inactivated in monocytes/granulocytes/macrophages but not Lin − Sca-1 + c-Kit + (LSK), Lin − Sca-1 − c-Kit + (LK) and lymphoid cells (Supplementary Figures S1B and C), and then determined if Tet2 f/f ;LysMCre mice develop myeloid malignancy as they age. Tet2 f/f ;Vav1Cre mice were used as positive control as animals with Tet2-inactivation in pan-hematopoietic cells (including HSC/HPCs) have been shown to develop myeloid malignancies. 6, 7 Consistently, aged Figure S1D ). In addition,~36% of the Tet2 f/f ;Vav1Cre mice, but none of the Tet2 f/f ; LysMCre and WT mice, died within 400 days of their life (Figure 1f ).
Therefore, aged Tet2 f/f ;Vav1Cre, but not Tet2 f/f ;LysMCre mice phenotypically show characteristics of CMML or MPN, demonstrating that deletion of Tet2 in differentiated myeloid cells is not sufficient to cause myeloid malignancy in mice. Transplantation of Tet2 − / − BM cells causes CMML-like phenotype in WT recipient mice. 5 Figure S2E ) phenotype displayed in Tet2 − / − mice. These data indicate that Tet2 loss in HSC/HPCs, but not differentiated hematopoietic cells, is capable of inducing myeloid malignancies in vivo. TET2 is a methylcytosine dioxygenase regulating cytosine hydroxymethylation in the genome. [10] [11] [12] Loss of Tet2 in HSC/HPCs increases their replating potential and repopulating capacity. 5, 14 We next examined the role of the TET2 catalytic activity in Tet2 loss-mediated hyper-replating potential in vitro and myeloid malignancy-initiating capacity in vivo by Tet2 − / − HSC/HPCs. We created lentiviral constructs using synthesized mammalian codonoptimized mouse Tet2 complementary DNA (cDNA) sequences (Tet2opt) and catalytic domain-inactive mutant Tet2 cDNA sequences (Tet2mu, H1295YxD1297A) to successfully overexpress FLAG-tagged Tet2opt and Tet2mu along with green flurescent protein (GFP) in both murine erythroleukemia (MEL) and Tet2 − / − Lin − c-Kit + cells (Figures 2a and b and Supplementary Figure S3A ). MEL cells are a mouse erythroleukemia cell line, arrested at the proerythroblast stage of development. Dot blot assays revealed a dramatically higher genomic 5hmC level in MEL cells overexpressing Tet2opt, whereas comparable 5hmC levels in MEL cells overexpressing Tet2mu as compared to cells expressing GFP alone (Figure 2c ). When replating assays were performed with GFP + Tet2 − / − Lin − c-Kit + cells expressing GFP, Tet2opt/GFP or Tet2mu/ GFP, significantly higher colony numbers were documented from Tet2 − / − Lin − c-Kit + cells expressing GFP or Tet2mu in round 2-5 of replating as compared to WT Lin − c-Kit + cells (Figure 2d ). By contrast, re-introducing Tet2opt into Tet2 − / − Lin − c-Kit + cells fully rescued their hyper-replating potential (Figure 2d ). Furthermore, the myeloid malignancy-initiating capacity of GFP + Tet2 − / − Lin − c-Kit + cells expressing GFP alone, Tet2opt/GFP or Tet2mu/GFP were determined by transplanting them into WT recipients (three mice/cell population) ( Supplementary Figures S3A and B) . Interestingly, 32 weeks after transplantation, 66.7% of the mice receiving Tet2 − / − Lin − c-Kit + cells expressing GFP alone or Tet2mu/GFP displayed monocytosis/neutrophilia, splenomegaly and increased proportion of Gr1 + /Mac1 + granulocytic/monocytic cells and Mac1 + F4/80 + monocytes in their BM, resembling CMML (Figures 2e-h) . By contrast, none of the mice receiving Tet2 − / − Lin − c-Kit + cells expressing Tet2opt/GFP exhibited any sign of abnormal hematopoiesis (Figures 2e-h) . These data indicate that re-introducing WT Tet2, but not the catalytic inactive mutant, rescued the myeloid malignancy-initiating capacity by Tet2 − / − Lin − c-Kit + cells. Thus, the catalytic activity of TET2 is essential and critical for its myeloid malignancy-suppressive function in HSC/HPCs.
In summary, TET2 requires its catalytic activity in HSC/HPCs to exert its myeloid malignancy-suppressive function. The TET2 mutations/deletions in myeloid malignancy patients are mostly heterozygous (haploinsufficient in TET2), [1] [2] [3] [4] and heterozygous TET2 mutations also occur in 45% of normal elderly individuals. 15 We have shown that Tet2-haploinsufficiency (Tet2 +/ − ) is sufficient to cause a CMML-like myeloid malignancy in mice. 5 Therefore, increasing the remaining WT TET2 enzymatic activity to compensate/overcome the TET2 haploinsufficiency in HSC/HPCs could represent an effective preventive and therapeutic strategy for individuals (including myeloid malignancy patients) with heterozygous TET2 mutations. Future work is warranted to identify agents that are capable of increasing the TET2 catalytic activity in vivo and to test the chemoprevention and therapeutic potential of these agents in animal models. Figure 2 . WT Tet2, but not catalytic domain-inactive mutant, is capable of rescuing the hyper-replating and myeloid malignancy-initiating potential by Tet2 − / − Lin − c-Kit + cells. (a) Schematic representation of the lentiviral vectors containing the mammalian codon-optimized cDNA sequences of mouse WT Flag-Tet2 (Tet2opt) or catalytic domain-inactive mutant Flag-Tet2 (Tet2mu, H1295YxD1297A). Both vectors contain a Flag-tag at their N-terminal. (b) MEL cells were transduced with lentivirus encoding GFP, Tet2opt/GFP or Tet2mu/GFP. Western blot was performed using whole-cell lysates prepared from GFP + MEL cells of each transduction with anti-Flag and anti-Actin antibodies. (c) Genomic DNA was extracted from GFP + MEL cells of each transduction and blotted onto nitrocellulose membrane after twofold-serial dilution. The 5hmC levels were detected with an anti-5hmC antibody. Methylene blue staining was performed to ensure equal spotting of total DNA on the membranes. Quantification of the signal density was shown in the left panel (mean ± s.d. of the 0.5, 1 and 2 μg DNA dot blots; relative to Tet2opt). (d) BM Lin − c-Kit + cells were isolated from 6-week-old WT or Tet2 − / − mice. Tet2 − / − Lin − c-Kit + cells were then transduced with lentivirus encoding GFP, Tet2opt/GFP or Tet2mu/GFP for 48 h. Colony-formation assays were then performed with WT Lin − c-Kit + cells and FACS-sorted GFP + Tet2 − / − Lin − c-Kit + cells of each transduction in methylcellulose medium (500 cells/plate). Colonies were passaged every 7 days for four sequential plating (P1-5). Data are shown as mean ± s.d., where each plating was performed in triplicate (representative of three independent experiments). *Po 0.05, **Po 0.01, ***P o0.001 (e-h) FACS-sorted GFP + Tet2 − / − Lin − c-Kit + cells (CD45.2 + ) of each transduction were transplanted into irradiated CD45.1 + B6.SJL recipients (Supplementary Figure S3B) . The recipients were sacrificed 32 weeks after transplantation for the following analyses: PB counts, May-Giemsa-stained PB smears (e), spleen size (f) and the GFP + cell chimerism (top) and the frequency of granulocytic/monocytic cells (Gr1/Mac1, middle) and monocytes (Mac1/F4/80, bottom) in the BM (g). Pie charts show the disease spectra in recipient mice transplanted with GFP + Tet2 − / − Lin − c-Kit + cells expressing GFP alone, Tet2opt/GFP or Tet2mu/GFP (h). Analyses on representative recipients receiving Tet2 − / − Lin − c-Kit + cells of each transduction are shown (e-g). AML cells are characterized by their recurrent contact with the stromal microenvironment in the bone marrow (BM). 1 This interplay between the BM stroma and AML cells protects malignant cells from spontaneous apoptosis, promotes proliferation and drug resistance. Increasing evidence suggests that this stromal refuge has a pivotal role in paving the way for disease relapse.
CXCL12 (also known as stromal-derived factor 1) and its cognate receptor CXCR4 represent critical components for the interaction between AML cells and BM stroma. 1 Thus, targeting the CXCL12/ CXCR4 signaling axis represents a promising therapeutic approach. 2 Culturing AML cells in the presence of CXCL12 promotes survival, while applying neutralizing CXCR4 antibodies, CXCL12 antibodies, or the CXCR4 inhibitor AMD3100 significantly reduces it. Preclinical in vivo models corroborate this data by showing that treatment with CXCR4 antibodies decreases AML burden in BM, peripheral blood and spleen. 3 Metabolic reprogramming represents an important hallmark of cancer. 4 Tumor-associated metabolic alterations provide accelerated energy supply and increased levels of biosynthetic precursors obligatory for rapid cell growth. In fact, enhanced aerobic glycolysis also known as the Warburg effect has been observed in AML and is linked to therapeutic resistance and adverse prognosis. 5 Blocking glycolysis alone or in combination with the chemotherapeutic cytarabine (Ara-C) has shown promising efficacy against AML cells. 6, 7 Previous studies have shown that the BM microenvironment can have an enhancing effect on the AML cells' glycolysis. 8 However, underlying stroma-derived signals are not fully elucidated.
Co-culturing AML cells with the BM-derived stromal cell line HS-5 prevents apoptosis and protects from drug-induced toxicity. 9 We utilized this well-established niche model for our experiments ( Supplementary Figure 1) . AML cell lines and primary CD33 + CD34 + AML cells ( Supplementary Figure 2) were cultured on HS-5 monolayers under normoxic conditions for 24 and 48 h as indicated. Stromal contact led to an increased basal glycolysis and an increased glycolytic capacity (Figure 1a ; Supplementary  Figure 3 ). Co-culture experiments using primary human BMderived mesenchymal stromal cells yielded comparable results ( Supplementary Figure 4) . With aerobic glycolysis being substantially boosted upon stromal contact energy production linked to the oxygen consumption rate that is indicative for respiration was found reduced (Supplementary Figure 5) .
As elevated glycolysis could be attributed to defective and thus inefficient mitochondrial function, we measured the basal oxygen consumption rate, which was actually increased following stromal Accepted article preview online 8 March 2016; advance online publication, 29 March 2016
